BIVIW — BioVie Inc. Warrant
NASDAQ
$0.29
+$0.00 (+0.00%)
BioVie Inc. Warrant (BIVIW) common stock listed on NASDAQ. It is led by Cuong Viet Do M.B.A., based in 680 W. Nye Lane, Carson City, NV, United States, 89703, with about 13 employees. BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Net income was -$5.1M.
Use this BIVIW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BIVIW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BIVIW SEC filings page. Lician reads the product cache first so this HTML stays unique to BioVie Inc. Warrant even when a live quote feed is slow.
About BioVie Inc. Warrant
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
BIVIW Key Statistics
Market Cap
$0.00M
Volume
21,870
Previous Close
$0.29
Day Range
$0.28 – $0.30
EPS
-$12.12
Revenue
$0.00
Net Income
-$17.54M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
13
BIVIW Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$17.54M | -$32.12M | -$50.26M | -$26.08M |
| EPS (Diluted) | -$12.12 | -$73.05 | -$15.47 | -$1.06 |
Total Assets
$21.56M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$17.54M
Operating Cash Flow
-$19.03M
Free Cash Flow
$0.00
BioVie Inc. Warrant Company Information
- President, CEO & Director
- Cuong Viet Do M.B.A.
- Headquarters
- 680 W. Nye Lane, Carson City, NV, United States, 89703
- Website
- bioviepharma.com
- Phone
- 775 888 3162
- IPO / Founded
- 2025-08-08